Clinical Trials | May 23, 2026
Eli lilly’s retatrutide delivers up to 30% weight loss in phase 3 trial
Clears major obesity endpoints at 80 weeks
Clears major obesity endpoints at 80 weeks
The approval was granted by Agenzia Italiana del Farmaco
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Pharma veteran with over three decades of industry experience to lead Alembic’s animal health growth and market expansion initiatives.
Diagnostic-guided healthcare platform strengthens leadership team to accelerate AI-driven diagnostics and consumer healthcare expansion
Eye care major expands network to 288 facilities across 10 countries after adding 57 new centres during FY26
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
AI and analytics leader brings extensive expertise in machine learning, GenAI, and life sciences decision intelligence to Lilly’s data science operations
Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
